Applied Therapeutics Q1 net loss $83.9M; govorestat NDA PDUFA Nov 28, 2024

Applied Therapeutics, Inc.

2024-Q1 EPS reported -$0.67 revenue$190,000

Net loss $83.9M ($0.67/share) vs $10.1M ($0.18/share) Q1 2023; cash $146.5M up from $49.9M.
Govorestat NDA for Classic Galactosemia under priority review; PDUFA date Nov 28, 2024.
MAA under EMA review; decision expected early Q1 2025 after Day 120 clock-stop extension.
Discussing potential NDA submission for SORD Deficiency under Accelerated Approval with FDA.
Appointed Dale Hooks as Chief Commercial Officer; presented Phase 3 ARISE-HF data at ACC.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Applied Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $146.5 million, net income $83.9 million, EPS $0.67 per basic and diluted common share.

Period: first quarter ended March 31, 2024
Revenue: $146.5 million
Net income: $83.9 million
EPS: $0.67 per basic and diluted common share
Result: reported results

Exact text from the filing

full study results were published in the Journal of the American College of Cardiology (JACC). Financial Results · Cash and cash equivalents and short-term investments totaled $146.5 million as of March 31, 2024, compared with $49.9 million at December 31, 2023. · Research and development expenses for the three months ended March 31, 2024, were $12.2 million,

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-059107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.